Abstract

The Release and Transdermal Penetration of Baclofen Formulated in a Poloxamer Lecithin Organogel

Author(s): Arnold John J, Asbill Scott

Issue: Nov/Dec 2009 - Geriatric Compounding

Page(s): 569-571

Download in electronic PDF format for $75
  • The Release and Transdermal Penetration of Baclofen Formulated in a Poloxamer Lecithin Organogel Page 1
  • The Release and Transdermal Penetration of Baclofen Formulated in a Poloxamer Lecithin Organogel Page 2
  • The Release and Transdermal Penetration of Baclofen Formulated in a Poloxamer Lecithin Organogel Page 3

Abstract

The purpose of this study was to evaluate the in vitro release and ex vivo penetration of baclofen following incorporation into a 2% poloxamer lecithin organogel. Franz cells were utilized for both the release and penetration studies. Semi-permeable dialysis membranes were used for the release testing, and porcine skin was used as the model skin for the penetration study. Baclofen release and penetration at predetermined time points were assessed using high-performance liquid chromatographic analysis. Results demonstrated that baclofen release from the poloxamer lecithin organogel was significantly higher than its penetration through porcine skin. The amount of baclofen released by the poloxamer lecithin organogel was linear up to 12 hours. Approximately 20% of applied drug was released over the duration of the study period. In comparison with drug released, the ex vivo penetration of baclofen through porcine skin was very low with only minute detectable quantities (significantly less than 1%) after the 12-ho

Related Keywords

  • baclofen
  • transdermal delivery
  • topical preparations
  • skin penetration
  • poloxamer lecithin organogel
  • dermal application
  • formulation
  • PLO
  • muscle relaxant

Related Categories

  • EXCIPIENTS
  • FORMULATIONS
  • PEER-REVIEWED
  • DOSAGE FORMS/DRUG CARRIERS
  • NEUROLOGY

Printer-Friendly Version

Related Articles from IJPC

Issue/Page
View/Buy		 Title/Author
(Click for Abstract / Details / Purchase)
Nov/Dec 2009
Pg. 569-571
The Release and Transdermal Penetration of Baclofen Formulated in a Poloxamer Lecithin Organogel
Author(s): Arnold John J, Asbill Scott
May/Jun 2013
Pg. 247-253
Effect of Formulation pH on Transdermal Penetration of Antiemetics Formulated in Poloxamer Lecithin Organogel
Author(s): Woodall Rachel, Arnold John J, McKay Doug, Abill C Scott
Mar/Apr 2003
Pg. 106-113
Veterinary Transdermal Medications: A to Z
Author(s): Davidson Gigi S
May/Jun 2014
Pg. 256-261
Preparation and In Vitro Evaluation of a Pluronic Lecithin Organogel Containing Ricinoleic Acid for Transdermal Delivery
Author(s): Boddu Sai HS, Bonam Sindhu Prabha, Wei Yangjie, Alexander Kenneth
Jan/Feb 2012
Pg. 62-63
The Use of Pluronic Lecithin Organogels in the Transdermal Delivery of Drugs
Author(s): Bramwell Bethany L, Williams LaVonn A
Nov/Dec 2014
Pg. 512-515
In Vitro Skin Penetration and Skin Content of Progesterone from Various Topical Formulations
Author(s): Heustess Allie, Asbill Scott, Eagerton David, Arnold John
Nov/Dec 2014
Pg. 504-511
Skin Penetration and Antinociception of Topical Gabapentin Formulations
Author(s): Bryson Evan, Asbill Scott, Sweitzer Sarah
Nov/Dec 2018
Pg. 498-503
Gabapentin in Elastic Liposomes: Preparation, Characterization, Drug Release, and Penetration Through Porcine Skin
Author(s): Le Uyen Minh, Baltzley Sarah, AlGhananeem Abeer
May/Jun 2016
Pg. 250-256
Effect of Penetration Enhancers on the Percutaneous Delivery of Pain Management Actives
Author(s): Trimble John, Light Bob
May/Jun 2003
Pg. 180-183
The History of Pluronic Lecithin Organogel: An Interview With Marty Jones, BSPharm, FACA, FIACP
Author(s): Allen Loyd V Jr
Nov/Dec 2010
Pg. 513
Baclofen 5%, Capcaicin 0.075%, Ketoprofen 10%, and Tetracaine 2% in Pluronic Lecithin Organogel
Author(s): Allen Loyd V Jr
Jan/Feb 2022
Pg. 65-71
Physical Stability and Release Profile of Compounded Gabapentin Containing Pluronic Lecithin Organogel for Neuropathic Pain Management
Author(s): Hong Eun Ji, Sumanasekera Wasana, Le Uyen Minh
Nov/Dec 2010
Pg. 514
Baclofen 5%, Gabapentin 5%, Ketoprofen 10%, and Lidocaine 5% in Pluronic Lecithin Organogel
Author(s): Allen Loyd V Jr
Nov/Dec 2010
Pg. 512
Amitriptyline Hydrochloride 2%, Baclofen 5%, Ketamine Hydrochloride 5%, Ketoprofen 10% in Pluronic Lecithin Organogel
Author(s): Allen Loyd V Jr
Mar/Apr 2004
Pg. 101-105
Pluronic Lecithin Organogel for Local Delivery of Anti-Inflammatory Drugs
Author(s): Frankum James, Ramsay Dale, Das Nandita G, Das Sudip K
May/Jun 2005
Pg. 242-246
Bioavailability of Promethazine in a Topical Pluronic Lecithin Organogel: A Pilot Study
Author(s): Glisson James K, Wood Rebecca L, Kyle Patrick B, Cleary John D
Nov/Dec 2010
Pg. 522-525
Stability of Methimazole in Poloxamer Lecithin Organogel to Determine Beyond-Use Date
Author(s): Pignato Alyssa, Pankaskie Marvin, Birnie Christine
Nov/Dec 2017
Pg. 530-535
Effect of Penetration Enhancers on the Percuaneous Delivery of Hormone Replacement Actives
Author(s): Trimble John O, Light Bob
Jul/Aug 2021
Pg. 322
BHR in PLO Gel (Benadryl, Haldol, and Reglan in Pluronic Lecithin Organogel)
Author(s): Allen Loyd V Jr
Mar/Apr 2015
Pg. 161-166
Skin Permeation and Antinociception of Compounded Topical Cyclobenzaprine Hydrochloride Formulations
Author(s): Bryson Evan, Hartman Rachel, Arnold John, Gorman Greg, Sweitzer Sarah.Asbill Scott